

Laurence Buisseret

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4191833/publications.pdf>

Version: 2024-02-01

18
papers

3,057
citations

567281

15
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

6041
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2460-2467.	1.6	1,185
2	The adenosine pathway in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 611-629.	27.6	275
3	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1785-1800.	8.2	266
4	CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. <i>JCI Insight</i> , 2017, 2, .	5.0	258
5	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	182
6	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. <i>Oncolmmunology</i> , 2017, 6, e1257452.	4.6	169
7	Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. <i>Annals of Oncology</i> , 2018, 29, 1056-1062.	1.2	138
8	Targeting immune checkpoints in breast cancer: an update of early results. <i>ESMO Open</i> , 2017, 2, e000255.	4.5	118
9	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. <i>Journal of the National Cancer Institute</i> , 2020, 112, 708-719.	6.3	111
10	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. <i>Cancer Research</i> , 2017, 77, 5652-5663.	0.9	90
11	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. <i>Modern Pathology</i> , 2017, 30, 1204-1212.	5.5	81
12	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2660.	4.8	65
13	A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	33
14	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 151.	5.0	30
15	Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis. <i>Oncolmmunology</i> , 2019, 8, 1601481.	4.6	24
16	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. , 2021, 9, e001965.		16
17	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). <i>Acta OncolÃ³gica</i> , 2020, 59, 723-725.	1.8	7
18	Management of early breast cancer in patients bearing germline BRCA mutations. <i>Seminars in Oncology</i> , 2020, 47, 243-248.	2.2	3